Abstract
Purpose
The aim of this study was to evaluate the efficacy of Mentha crispa in the treatment of women with Trichomonas vaginalis infection (TVI).
Methods
This was a randomized, double-blind, and controlled clinical trial consisting of three phases, pre-treatment, treatment, and post-treatment. Sixty female patients were randomized to a treatment group, M. crispa (24 mg) or secnidazole (2,000 mg), both consisting of single dose.
Results
After treatment the proportion of patients without TVI in secnidazole group was 96.6% and in the M. crispa group was 90%, no difference was found between groups (P = 0.6120). We observed improvement in vaginal discharge, malodorous vaginal secretion, dyspareunia, dysuria, pelvic pain, and burning and itching in the genital area in patients of both groups of treatment, with no statistically significant differences between them (P > 0.05). Adverse effects were significantly higher (P = 0.0006) in the secnidazole group (66.6%) than in the M. crispa group (20%), that being mostly nausea and metallic taste with statistically significant differences between treatment groups (P < 0.001).
Conclusion
This study is the first to show that M. crispa is effective and safe, representing an alternative for the treatment of TVI in women.
Similar content being viewed by others
References
Domeika M, Zhurauskaya L, Savicheva A, Frigo N, Sokolovskiy E, Hallén A, Unemo M, Ballard RC (2010) Guidelines for the laboratory diagnosis of trichomoniasis in East European countries. J Eur Acad Dermatol Venereol 24:1–10
Kissinger P, Amedee A, Clark RA, Dumestre J, Theall KP, Myers L, Hagensee ME, Farley TA, Martin DH (2009) Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 36:11–16
Mann JR, McDermott S, Barnes TL, Hardin J, Bao H, Zhou L (2009) Trichomoniasis in pregnancy and mental retardation in children. Ann Epidemiol 19:891–899
Depuydt CE, Leuridan E, Damme PV, Bogers J, Vereecken AJ, Donders GGG (2010) Epidemiology of Trichomonas vaginalis and Human Papillomavirus infection detected by real-time PCR in flanders. Gynecol Obstet Invest 70:273–280
Hardman JG, Limbird LE, Gilman AG (2005) Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York
Soper D (2004) Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol 190:281–290
Gillis JC, Wiseman LR (1996) Secnidazole: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 51:621–638
Cunha GH, Fechine FV, Santos LKX, Pontes AVP, Oliveira JC, Moraes MO, Bezerra FAF, Moraes MEA (2011) Efficacy of the tincture of jalapa in the treatment of functional constipation: a double-blind, randomized, placebo-controlled study. Contemp Clin Trials 32:153–159
Terauchi M, Hiramitsu S, Akiyoshi M, Owa Y, Kato K, Obayashi S, Matsushima E, Kubota T (2011) Effects of three Kampo formulae: Tokishakuyakusan (TJ-23), Kamishoyosan (TJ-24), and Keishibukuryogan (TJ-25) on Japanese peri- and postmenopausal women with sleep disturbances. Arch Gynecol Obstet 284:913–921
Teles NSB, Fechine FV, Viana FAC, Viana IOL, Nascimento DF, Leite ALAS, Frota Bezerra FA, Moraes MO, Moraes MEA (2011) Evaluation of the therapeutic efficacy of Mentha crispa in the treatment of giardiasis. Contemp Clin Trials 32:809–813
Dimech GS, Gonçalves ES, Araújo AV, Arruda VM, Baratella-Evêncio L, Wanderley AG (2006) Evaluation of the hydroalcoholic extract of Mentha crispa on the reproductive performance in Wistar rats. Braz J Pharmacogn 16:152–157
(2010) Drugs for sexually transmitted infections. Treat Guidel Med Lett 95:53–60. http://secure.medicalletter.org/TG-article-95a. Accessed 14 June 2011
Santana CF, Almeida ER, Santos ER, Souza IA (1992) Action of Mentha crispa hydroethanolic extract in patients bearing intestinal protozoan. Fitoterapia 63:409–410
Leon SR, Konda KA, Bernstein KT, Pajuelo JB, Rosasco AM, Caceres CF, Coates TJ, Klausner JD (2009) Trichomonas vaginalis infection and associated risk factors in a socially-marginalized female population in coastal Peru. Infect Dis Obstet Gynecol. doi:10.1155/2009/752437
Hilber AM, Francis SC, Chersich M, Scott P, Redmond S, Bender N, Miotti P, Temmerman M, Low N (2010) Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis. PLoS ONE 5:1–11
Swygard H, Seña AC, Hobbs MM, Cohen MS (2004) Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Dis 80:91–95
Fichorova RN (2009) Impact of T. vaginalis infection on innate immune responses and reproductive outcome. J Reprod Immunol 83:185–189
Gülmezoglu AM (2007) Interventions for trichomoniasis in pregnancy (review). Cochrane Collab 4:1–9
Chersich MF, Rees HV (2008) Vulnerability of women in southern Africa to infection with HIV: biological determinants and priority health sector interventions. AIDS 22:27–40
Schneider H, Coetzee DJ, Fehler HG, Bellingan A, Dangor Y, Radebe F, Ballard RC (1998) Screening for sexually transmitted diseases in rural South African women. Sex Transm Dis 74:147–152
Moodley P, Connolly C, Sturm W (2002) Interrelationships among HIV type 1 infection, bacterial vaginosis, trichomoniasis and the presence of yeasts. J Infect Dis 185:69–73
Brabin L (2001) Hormonal markers of susceptibility to sexually transmitted infections: Are we taking them seriously? BMJ 323:394–395
Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK (2001) Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. Am J Obstet Gynecol 185:380–385
Morrison CS, Bright P, Wong EL, Kwok C, Yacobson I, Gaydos CA, Tucker HT, Blumenthal PD (2004) Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis 31:561–567
Mohllajee AP, Curtis KM, Martins SL, Peterson HB (2006) Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review. Contraception 73:154–165
Vera EG, Orozco HH, Soto SS, Aburto EL (2008) Condom effectiveness to prevent sexually transmitted diseases. Ginecol Obstet Mex 76:88–96
Buitrón GFR, Gonzalo BLF, Oropez RG, Romero-Cabello R (1997) Comparative study for the evaluation of the efficacy and safety of metronidazole and secnidazole in the treatment of vaginal trichomoniasis. Ginecol Obstet Mex 65:487–491
Bohbot JM, Vicaut E, Fagnen D, Brauman M (2010) Treatment of bacterial vaginosis: a multicenter, double-blind, doubly-dummy, randomized phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol. doi:10.1155/2010/705692
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moraes, M.E.A., Cunha, G.H., Bezerra, M.M. et al. Efficacy of the Mentha crispa in the treatment of women with Trichomonas vaginalis infection. Arch Gynecol Obstet 286, 125–130 (2012). https://doi.org/10.1007/s00404-012-2251-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-012-2251-4